Detalhe da pesquisa
1.
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
J Neurooncol
; 155(3): 363-372, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34761331
2.
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Cancer
; 126(12): 2821-2828, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32154928
3.
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
J Neurooncol
; 136(1): 79-86, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28988377
4.
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
J Neurooncol
; 126(2): 309-16, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26508094
5.
Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.
Cancer
; 121(23): 4165-72, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26308485
6.
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.
J Neurooncol
; 122(2): 409-17, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25682091
7.
Pulsed reduced-dose rate re-irradiation for patients with recurrent grade 2 gliomas.
Neurooncol Adv
; 6(1): vdae073, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38845694
8.
Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase.
J Oncol Pharm Pract
; 19(3): 269-72, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23154571
9.
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited.
Lancet Oncol
; 18(12): e708, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29208432
10.
Case report: Radiographic complete response of radiation-induced glioblastoma to front-line radiotherapy: A report and molecular characterization of two unique cases.
Front Neurol
; 14: 1099424, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37025206
11.
NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma.
Neurooncol Adv
; 5(1): vdad116, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38024244
12.
Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825.
Neurooncol Adv
; 4(1): vdac152, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36299794
13.
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Neuro Oncol
; 23(3): 468-477, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33085768
14.
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma.
Neurosurgery
; 88(2): 246-251, 2021 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33027815
15.
Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825).
Neuro Oncol
; 23(7): 1125-1138, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33515019
16.
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
J Neurooncol
; 96(2): 211-7, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19562255
17.
Pulsed Reduced Dose Rate for Reirradiation of Recurrent Breast Cancer.
Pract Radiat Oncol
; 10(2): e61-e70, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31526900
18.
[124I]CLR1404 PET/CT in High-Grade Primary and Metastatic Brain Tumors.
Mol Imaging Biol
; 22(2): 434-443, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31183841
19.
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.
Neurooncol Adv
; 2(1): vdaa124, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33235994
20.
Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiated chest wall, axilla, or supraclavicular region.
Breast Cancer Res Treat
; 114(2): 307-13, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18389365